Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients

Journal of Clinical Pharmacology

Volumn 51, Issue 5, 2011, Pages 661-671

  Ignjatovic, Anita Rakic ^a   Miljkovic, Branislava ^b   Todorovic, Dejan ^b   Timotijevic, Ivana ^b   Pokrajac, Milena ^b  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

depressive patients; Moclobemide; predictive performance; single point sampling strategies; systemic exposure

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ATENOLOL; BROMAZEPAM; CARBAMAZEPINE; CEFALEXIN; DIAZEPAM; ENALAPRIL; FAMOTIDINE; LORAZEPAM; METOPROLOL; MOCLOBEMIDE; NIFEDIPINE; NITRAZEPAM; PROPRANOLOL; RANITIDINE; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; FEMALE; HUMAN; LIMIT OF QUANTITATION; MALE; MEASUREMENT ERROR; PREDICTION; STEADY STATE; TREATMENT RESPONSE; VALIDATION THERAPY;

ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INPATIENTS; LINEAR MODELS; MALE; MIDDLE AGED; MOCLOBEMIDE; MODELS, BIOLOGICAL; MONOAMINE OXIDASE INHIBITORS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SERBIA;

EID: 79955541937     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010372105     Document Type: Article

References (44)

1. Filler G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy. Transpl Int. 2004 ; 17: 120-125 (Pubitemid 38660687)
2. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet. 1995 ; 29: 292-332
3. Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand. 1990 ; 360 (suppl). 91-93 (Pubitemid 20320309)
4. Therapeutic Drugs. 2 nd ed. Dollery C, ed. Edinburg, UK: Churchill Livingstone ; 1999 :
5. Bonnet U. Moclobemide: evolution, pharmacodynamic and pharmacokinetic properties. CNS Drug Rev. 2002 ; 8: 283-308 (Pubitemid 35191287)
6. Stoeckel K, Pfefen JP, Mayersohn M, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand. 1990 ; 360 (suppl). 94-7 (Pubitemid 20320310)
7. Zimmer R, Gieschke R, Fischbach R, Gasic S. Interaction studies with moclobemide. Acta Psychiatr Scand. 1990 ; 360 (suppl). 84-86 (Pubitemid 20320307)
8. Amrein R, Guetert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology. 1992 ; 106: S24 - S31
9. Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 ; 69: 266-273
10. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 ; 57: 670-677
11. Kirchheiner J, Brøsen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001 ; 104: 173-192 (Pubitemid 32762271)
12. Guentert TW, Banken L, Hilton S, Holford N. Moclobemide: relationship between dose, drug concentration in plasma, and occurrence of adverse events. J Clin Psychopharmacol. 1995 ; 15 (suppl 2). 84S - 94S
13. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta analysis and prospective studies. J Clin Psychopharmacol. 1995 ; 15 (4 suppl 2). 16S - 23S
14. Gex-Fabry M, Balant-Gorgia A, Luc PB. Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability of moclobemide. Ther Drug Monit. 1995 ; 17: 39-46
15. Op den Buijsch RAM, van de Plas A, Stolk LML, et al. Evaluation of limited sampling strategies for tacrolimus. Eur J Clin Pharmacol. 2007 ; 63: 1039-1044 (Pubitemid 47561802)
16. Cattaneo D, Cortinovis M, Baldelli S, Gotti E, Remuzzi G, Petrico N. Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on calcineurin inhibitor free regimen. J Clin Pharmacol. 2009 ; 49: 773-781
17. Guido F, Ingrim F. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit. 2000 ; 22: 169-173
18. Ting LSL, Partovi N, Laevy RD, Riggs KW, Ensom MHH. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients. Pharmacotherapy. 2006 ; 26: 1232-1240 (Pubitemid 44306882)
19. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005 ; 67: 2440-2447 (Pubitemid 41623408)
20. Meier-Kriesche HU, Alloway R, Gaber OA, Canafax DM, Kaplan B. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. J Clin Pharmacol. 1999 ; 39: 166-171 (Pubitemid 29068162)
21. Wang CH, Chou NK, Wu FLL, et al. Therapeutic drug monitoring of cyclosporine neural in de novo Chinese cardiac transplant recipients treated with everolimus-cyclosporine immunosuppressive regimen. Transplant Proceed. 2006 ; 38: 2132-2134
22. Vartan M, Giannetti N, Cecere R, Benser JG, Cantarovich M. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus. J Heart Lung Transplant. 2005 ; 24: 1614-1618 (Pubitemid 41396461)
23. Muindi JR, Wilson JW, Peng Y, Capozolli MJ, Johnson CS, Trump DL. A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. J Clin Pharmacol. 2003 ; 43: 894-900 (Pubitemid 36886109)
24. Rakic Ignjatovic A, Miljkovic B, Todorovic D, Timotijevic I, Pokrajac M. Moclobemide monotherapy vs combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study. Br J Clin Pharmacol. 2009 ; 67: 199-208
25. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev. 2003 ; 9: 97-140 (Pubitemid 36438138)
26. Rakic A, Miljkovic B, Pokrajac M, Vucicevic K. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. J Pharm Biomed Anal. 2007 ; 43: 1416-1422
27. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut. 1981 ; 9: 503-512
28. Kim JS, Nafziger AN, Tsunoda SM, et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol. 2002 ; 42: 376-382 (Pubitemid 34259770)
29. Ma JD, Nafziger AN, Kashuba ADM, et al. Limited sampling strategy of S-warfaring concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 ; 44: 570-576 (Pubitemid 38668018)
30. Lee LS, Bertino JS, Nfziger AN. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol. 2006 ; 46: 229-234 (Pubitemid 43146452)
31. Mahmood I. A comparative computer simulation of three different sparse-sampling methods for the estimation of steady-state area under the concentration-time curve (AUC) and maximum concentration (Cmax) in toxicokinetics. J Pharm Sci. 1997 ; 86: 579-583 (Pubitemid 27203405)
32. Mahmood I, Mahayni H. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies. Int J Clin Pharmacol Ther. 1999 ; 37: 275-281 (Pubitemid 29263769)
33. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 ; 1: 307-310 (Pubitemid 16134762)
34. Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 ; 52: 450-74 (Pubitemid 26293868)
35. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003 ; 2: 473-81 (Pubitemid 36876104)
36. Spina E, Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 ; 100: 4-22 (Pubitemid 46051438)
37. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003 ; 17: 517-538 (Pubitemid 37215077)
38. Shelton RC. Mood-stabilizing drugs in depression. J Clin Psychiatry. 1999 ; 60 (suppl 5). 37-40
39. Montgomery SA, Schatzberg AF, Gueli JD, Kasper S, Nameroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord. 2000 ; 59: S39 - S56
40. Post R, Speer AM, Obrocea GV, Leverich GS. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res. 2002 ; 2: 228-251 (Pubitemid 35375336)
41. Sadock BJ, Sadock VA, Sussman N Kaplan & Sadock's Pocket Handbook of Psychiatric Drug Treatment. 4 th ed. Philadelphia, Pa: Lippincott Williams & Wilkins ; 2006 :
42. Silverstone PH, Silverstone T. A review of acute treatments for bipolar depression. Int Clin Pharmacol. 2004 ; 19: 113-24 (Pubitemid 38586482)
43. Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord. 2005 ; 84: 243-249 (Pubitemid 40222506)
44. Balram C, Sivathasan C, Cheung YB, Tan SB, Tan YS. A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients. J Heart Lung Transplant. 2002 ; 21: 1016-1021 (Pubitemid 35286685)